Pharsight

Novo patents expiration

1. Fiasp patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324157 NOVO Preparation comprising insulin, nicotinamide and an amino acid
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 19, 2022
New Product(NP) Sep 29, 2020
M(M-247) Oct 21, 2022

Drugs and Companies using INSULIN ASPART ingredient

Market Authorisation Date: 29 September, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage

FIASP family patents

Family Patents

2. Fiasp Flextouch patents expiration

FIASP FLEXTOUCH's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(11 months ago)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(23 days ago)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US7686786 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US8324157 NOVO Preparation comprising insulin, nicotinamide and an amino acid
Jun, 2030

(6 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 19, 2022
New Product(NP) Sep 29, 2020
M(M-247) Oct 21, 2022

Drugs and Companies using INSULIN ASPART ingredient

Market Authorisation Date: 29 September, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

FIASP FLEXTOUCH family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Macrilen patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6861409 NOVO Growth hormone secretagogues
Aug, 2022

(1 year, 10 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719 NOVO Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
Oct, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-170) Dec 20, 2024
New Chemical Entity Exclusivity(NCE) Dec 20, 2022

Drugs and Companies using MACIMORELIN ACETATE ingredient

NCE-1 date: 20 December, 2021

Market Authorisation Date: 20 December, 2017

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin

Dosage: FOR SOLUTION;ORAL

More Information on Dosage

MACRILEN family patents

Family Patents

4. Ozempic patents expiration

What is Ozempic?

Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.

What is the Ozempic controversy?

The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.

OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(1 year, 9 months from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(11 months ago)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(23 days ago)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(1 year, 1 month from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US11311679 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

US10335462 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-185) Mar 28, 2025
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
New Indication(I-822) Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indicated as an adjunct to diet and exercise to imp...

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage

OZEMPIC family patents

Family Patents

5. Rivfloza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11359203 NOVO Therapeutic inhibition of lactate dehydrogenase and agents therefor
Oct, 2035

(11 years from now)

US10738311 NOVO Therapeutic inhibition of lactate dehydrogenase and agents therefor
Oct, 2035

(11 years from now)

US10351854 NOVO Therapeutic inhibition of lactate dehydrogenase and agents therefor
Oct, 2035

(11 years from now)

US11053502 NOVO Therapeutic inhibition of lactate dehydrogenase and agents therefor
Oct, 2035

(11 years from now)

US11661604 NOVO Methods and compositions for inhibiting expression of LDHA
Oct, 2038

(14 years from now)

US11286488 NOVO Methods and compositions for inhibiting expression of LDHA
Oct, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-443) Sep 29, 2030
New Chemical Entity Exclusivity(NCE) Sep 29, 2028

Drugs and Companies using NEDOSIRAN SODIUM ingredient

NCE-1 date: 30 September, 2027

Market Authorisation Date: 29 September, 2023

Treatment: Method of treating primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;INJECTION

More Information on Dosage

RIVFLOZA family patents

Family Patents

6. Rybelsus patents expiration

RYBELSUS's oppositions filed in EPO
RYBELSUS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(1 year, 9 months from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11382957 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(7 years from now)

US9278123 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(7 years from now)

US10960052 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid
Dec, 2031

(7 years from now)

US10086047 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(7 years from now)

US11759503 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(8 years from now)

US11759502 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(8 years from now)

US11759501 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(8 years from now)

US10933120 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(8 years from now)

US10278923 NOVO Oral dosing of GLP-1 compounds
May, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 20, 2022
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
M(M-252) Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 20 September, 2019

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage

RYBELSUS family patents

Family Patents

7. Ryzodeg 70/30 patents expiration

RYZODEG 70/30's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7615532 NOVO Insulin derivatives
Jun, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5866538 NOVO Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(11 months ago)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(23 days ago)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US7686786 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

US9884094 NOVO Method of treating diabetes mellitus
May, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 16, 2019
New Chemical Entity Exclusivity(NCE) Sep 25, 2020

Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 25 September, 2015

Treatment: Method of improving glycemic control in patients with diabetes mellitus by administering a mixture of insulin degludec and insulin aspart during or around the time of the largest meal of the day

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

RYZODEG 70/30 family patents

Family Patents

8. Saxenda patents expiration

SAXENDA's oppositions filed in EPO
SAXENDA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6458924 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US7235627 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US6268343 NOVO Derivatives of GLP-1 analogs
Aug, 2022

(1 year, 9 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8846618 NOVO Stable formulation of modified GLP-1
Jun, 2022

(1 year, 11 months ago)

US6899699

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 11 months ago)

US8672898

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 11 months ago)

US9486588

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 11 months ago)

US8846618

(Pediatric)

NOVO Stable formulation of modified GLP-1
Dec, 2022

(1 year, 5 months ago)

US6268343

(Pediatric)

NOVO Derivatives of GLP-1 analogs
Feb, 2023

(1 year, 3 months ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(11 months ago)

US8579869

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(5 months ago)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(23 days ago)

US7762994

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(5 months from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(1 year, 1 month from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US11311679 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US8114833

(Pediatric)

NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Feb, 2026

(1 year, 7 months from now)

US8684969

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Apr, 2026

(1 year, 10 months from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US9861757

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Jul, 2026

(2 years from now)

US9616180

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(2 years from now)

US9108002

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US7686786 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US10220155

(Pediatric)

NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jan, 2027

(2 years from now)

US8920383

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(2 years from now)

US9775953

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(2 years from now)

USRE46363

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Feb, 2027

(2 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9687611

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Aug, 2027

(3 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9457154

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Mar, 2028

(3 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Aug, 2032

(8 years from now)

US9968659 NOVO Liraglutide in cardiovascular conditions
Jan, 2037

(12 years from now)

US9968659

(Pediatric)

NOVO Liraglutide in cardiovascular conditions
Jul, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 04, 2023
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

9. Tresiba patents expiration

TRESIBA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7615532 NOVO Insulin derivatives
Jun, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(11 months ago)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(23 days ago)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US7686786 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 16, 2019
New Chemical Entity Exclusivity(NCE) Sep 25, 2020

Drugs and Companies using INSULIN DEGLUDEC ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 21 November, 2018

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

TRESIBA family patents

Family Patents

10. Wegovy patents expiration

WEGOVY's oppositions filed in EPO
WEGOVY IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(1 year, 9 months from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(9 years from now)

US11752198 NOVO GLP-1 compositions and uses thereof
Aug, 2038

(14 years from now)

US10888605 NOVO GLP-1 compositions and uses thereof
Aug, 2038

(14 years from now)

US11318191 NOVO GLP-1 compositions and uses thereof
Feb, 2041

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 04, 2024
New Dosing Schedule(D-190) Jul 21, 2026
New Indication(I-935) Mar 08, 2027
New Patient Population(NPP) Dec 23, 2025
New Chemical Entity Exclusivity(NCE) Dec 05, 2022

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of WEGOVY before it's drug patent expiration?
More Information on Dosage

WEGOVY family patents

Family Patents

11. Xultophy 100/3.6 patents expiration

XULTOPHY 100/3.6's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7235627 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US6458924 NOVO Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US8846618 NOVO Stable formulation of modified GLP-1
Jun, 2022

(1 year, 11 months ago)

US6268343 NOVO Derivatives of GLP-1 analogs
Aug, 2022

(1 year, 9 months ago)

US7615532 NOVO Insulin derivatives
Jun, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US6899699

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 11 months ago)

US9486588

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 11 months ago)

US8672898

(Pediatric)

NOVO Automatic injection device with reset feature
Jul, 2022

(1 year, 11 months ago)

US8846618

(Pediatric)

NOVO Stable formulation of modified GLP-1
Dec, 2022

(1 year, 5 months ago)

US6268343

(Pediatric)

NOVO Derivatives of GLP-1 analogs
Feb, 2023

(1 year, 3 months ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(11 months ago)

US8579869

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(5 months ago)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(23 days ago)

US7762994

(Pediatric)

NOVO Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(5 months from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 4 months from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 7 months from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 7 months from now)

US8684969

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Apr, 2026

(1 year, 10 months from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US9861757

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Jul, 2026

(2 years from now)

US9616180

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(2 years from now)

US9108002

(Pediatric)

NOVO Automatic injection device with a top release mechanism
Jul, 2026

(2 years from now)

US7686786 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US8920383

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(2 years from now)

US9775953

(Pediatric)

NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jan, 2027

(2 years from now)

US10220155

(Pediatric)

NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jan, 2027

(2 years from now)

USRE46363

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Feb, 2027

(2 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9687611

(Pediatric)

NOVO Injection device with torsion spring and rotatable display
Aug, 2027

(3 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9457154

(Pediatric)

NOVO Injection device with an end of dose feedback mechanism
Mar, 2028

(3 years from now)

US8937042 NOVO Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
May, 2029

(4 years from now)

US8937042

(Pediatric)

NOVO Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
Nov, 2029

(5 years from now)

US7615532

(Pediatric)

NOVO Insulin derivatives
Dec, 2029

(5 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-242) Aug 08, 2022
New Combination(NC) Nov 21, 2019
New Chemical Entity Exclusivity(NCE) Sep 25, 2020

Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient

NCE-1 date: 26 September, 2019

Market Authorisation Date: 21 November, 2016

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

XULTOPHY 100/3.6 family patents

Family Patents